Literature DB >> 29654101

Anti-TNF therapy-induced lupus erythematosus-like syndrome in a patient treated with adalimumab for cutaneous psoriasis.

Julie E Stein1, Jeffrey Patterson-Fortin1, Benjamin E Bodnar1.   

Abstract

A 44-year-old woman with cutaneous psoriasis and no history of joint involvement recently treated with adalimumab was admitted to the inpatient Internal Medicine service for uncontrolled, severe joint pain so debilitating that it limited her activities of daily living and prevented her from working as a medical technologist. She had stopped taking adalimumab 3 weeks prior to presentation after receiving approximately 2.5 months of therapy for cutaneous psoriasis unresponsive to trials of topical steroids and methotrexate. Antinuclear antibody and anti-double-stranded DNA antibodies were positive at high titres. She received a course of oral corticosteroids with improvement in her symptoms. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  dermatology; immunological products and vaccines; musculoskeletal syndromes; systemic lupus erythematosus

Mesh:

Substances:

Year:  2018        PMID: 29654101      PMCID: PMC5905774          DOI: 10.1136/bcr-2017-223473

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association.

Authors:  Michael H Gewitz; Robert S Baltimore; Lloyd Y Tani; Craig A Sable; Stanford T Shulman; Jonathan Carapetis; Bo Remenyi; Kathryn A Taubert; Ann F Bolger; Lee Beerman; Bongani M Mayosi; Andrea Beaton; Natesa G Pandian; Edward L Kaplan
Journal:  Circulation       Date:  2015-04-23       Impact factor: 29.690

2.  Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic.

Authors:  David A Wetter; Mark D P Davis
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

Review 3.  TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.

Authors:  Victoria L Williams; Philip R Cohen
Journal:  Int J Dermatol       Date:  2011-05       Impact factor: 2.736

Review 4.  Anti-TNF-induced lupus.

Authors:  Emma L Williams; Stephan Gadola; Christopher J Edwards
Journal:  Rheumatology (Oxford)       Date:  2009-05-04       Impact factor: 7.580

5.  Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Sandra Muñoz; Natalia Soria; Diana Galiana; Laura Bertolaccini; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Medicine (Baltimore)       Date:  2007-07       Impact factor: 1.889

6.  Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

Authors:  Dennis A Revicki; Mary Kaye Willian; Alan Menter; Kenneth B Gordon; Alexa B Kimball; Craig L Leonardi; Richard G Langley; Miriam Kimel; Martin Okun
Journal:  J Dermatolog Treat       Date:  2007       Impact factor: 3.359

7.  Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.

Authors:  Vibeke Strand; Ronald F van Vollenhoven; Eun Bong Lee; Roy Fleischmann; Samuel H Zwillich; David Gruben; Tamas Koncz; Bethanie Wilkinson; Gene Wallenstein
Journal:  Rheumatology (Oxford)       Date:  2016-02-29       Impact factor: 7.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.